SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Re-Appointment Of Managing Director And Independent Director
attached30-05-2022
Q4FY22 Quarterly Result Announced for Sun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries declares Q4FY22 result: Full Year FY22 gross sales up 15.6% YoY, EBITDA up 23.6% & Adjusted Net Profit up 29% FY22 ROCE improved 288bps to 16.4%, ROIC by 306bps to 21% & ROE by 256bps to 15% Q4 Gross sales up 11% YoY, EBITDA up 14.6% & Adjusted Net Profit up 18% Highlights of full year FY22 consolidated financials: Consolidated sales from operations at Rs. 384,264 million, growth of 15.6% over same period last year. India formulation sales at Rs. 127,593 million, up by 23% over same period last year. US formulation sales at US$ 1,526 million up by 12% over same period last year. Emerging Markets formulation sales at US$ 905 million up by 16% over same period last year. Rest of World formulation sales at US$ 732 million, up by 11% over same period last year. R&D; investments at Rs. 22,194 million compared to Rs. 21,499 million for FY22 EBITDA at Rs. 101,697 million up about 23.6% over last year, with EBITDA margin at 26.5%, an expansion of 170bps YoY. Excluding the exceptional items, adjusted net profit for FY22 was at Rs. 76,671 million, up about 29% YoY. Reported net profit for full year FY22 was at Rs. 32,727 million compared to Rs. 29,038 million, up by about 13% over last year. Excluding exceptional items, ROCE improved by 288bps to 16.4%, ROIC by 306bps to 21% while ROE has improved by 256bps to 15% Highlights of Q4FY22 consolidated financials: Consolidated sales from operations at Rs. 93,861 million, growth of 11% over Q4 last year India formulation sales at Rs. 30,956 million, up 16% over same quarter last year US formulation sales at US$ 389 million, growth of 5% over Q4 last year Emerging Markets formulation sales at US$ 206 million, up by 7% over Q4 last year Rest of World formulation sales at US$ 178 million, up by 7% over same quarter last year R&D; investments at Rs. 5,433 million compared to Rs. 5,571 million for Q4FY21 EBITDA at Rs. 22,797 million, up by about 14.6% over Q4 last year, with EBITDA margin at 24.3% Adjusted net profit for the quarter was at Rs. 15,821 million, up by 18% YoY, after excluding the exceptional items of Rs. 39,357 million & exceptional tax gain of Rs. 764 million. Reported net loss for Q4FY22 was at Rs. 22,772 million. Dilip Shanghvi, Managing Director of the Company said, “FY22 was a good year with strong topline and EBITDA growth. All our geographies have recorded double digit growth and profitability has improved despite rising costs. The specialty business continues to ramp-up strongly with global Ilumya sales recording 81% growth to reach US$315 million in FY22. Our India business continues to grow faster than market, leading to increase in market share. We continue to focus on expanding our global specialty business, growing all our businesses and on improving operational efficiencies.” Result PDF30-05-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to financial results for the fourth quarter and full year ending March 31st, 2022.30-05-2022
Sun Pharma acquires Uractiv portfolio from Fiterman Pharma in Romania
The Uractiv portfolio comprises food supplements including minerals, vitamins and adjuvants; cosmetics and medical devices used for maintaining urinary tract health.27-05-2022